secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001193125-25-209437
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes
--------------------------------------------------------------------------------

- Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.
- Used ~$402.5M cash and 2,168,806 common shares to exchange $399.5M of existing 3.50% notes due 2027.
- Initial conversion price ~$68.42 per share, ~37.5% premium over $49.76 last sale price.
- Remaining proceeds to fund aficamten commercial launch, development, pipeline, and general corporate purposes.
- Notes not redeemable before Oct 6, 2028; convertible under certain stock price and event conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/d933506d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-209437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer